These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21105944)

  • 21. Continuing medical education effect on practice performance: effectiveness of continuing medical education: American College of Chest Physicians Evidence-Based Educational Guidelines.
    Davis D; Galbraith R;
    Chest; 2009 Mar; 135(3 Suppl):42S-48S. PubMed ID: 19265075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in drug prescribing patterns related to commercial company funding of continuing medical education.
    Bowman MA; Pearle DL
    J Contin Educ Health Prof; 1988; 8(1):13-20. PubMed ID: 10294441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An insider's perspective: defense of the pharmaceutical industry's marketing practices.
    Johar K
    Albany Law Rev; 2012-2013; 76(1):299-334. PubMed ID: 23577377
    [No Abstract]   [Full Text] [Related]  

  • 24. Quest of prescribing practice in Pakistan.
    Shiwani MH
    J Pak Med Assoc; 2006 May; 56(5):249-50. PubMed ID: 16767958
    [No Abstract]   [Full Text] [Related]  

  • 25. Continuing medical education effect on physician knowledge application and psychomotor skills: effectiveness of continuing medical education: American College of Chest Physicians Evidence-Based Educational Guidelines.
    O'Neil KM; Addrizzo-Harris DJ;
    Chest; 2009 Mar; 135(3 Suppl):37S-41S. PubMed ID: 19265074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conflicts of interest, institutional corruption, and pharma: an agenda for reform.
    Rodwin MA
    J Law Med Ethics; 2012; 40(3):511-22. PubMed ID: 23061578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ethical relationships between drug companies and the medical profession.
    Rosner F
    Chest; 1992 Jul; 102(1):266-9. PubMed ID: 1623765
    [No Abstract]   [Full Text] [Related]  

  • 28. Academia-industry collaboration in continuing medical education: description of two approaches.
    Katz HP; Goldfinger SE; Fletcher SW
    J Contin Educ Health Prof; 2002; 22(1):43-54. PubMed ID: 12004640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "The judgment is reversed".
    Northup GW
    J Am Osteopath Assoc; 2001 Jun; 101(6):359-60. PubMed ID: 11436874
    [No Abstract]   [Full Text] [Related]  

  • 30. Gifts to physicians from the pharmaceutical and medical manufacturing industry: what every physician should know.
    Zoorob R; Larzelere M
    J La State Med Soc; 2004; 156(1):28-32. PubMed ID: 15000210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physician education and the pharmaceutical industry.
    Johnson RG
    Chest; 2001 Apr; 119(4):995-6. PubMed ID: 11296157
    [No Abstract]   [Full Text] [Related]  

  • 32. Medical commerce, physician entrepreneurialism, and conflicts of interest.
    Rodwin MA
    Camb Q Healthc Ethics; 2007; 16(4):387-97; discussion 439-42. PubMed ID: 18018918
    [No Abstract]   [Full Text] [Related]  

  • 33. [The doctor as seen by advertisements of drug companies of the 20th century].
    Bonnemain B
    Hist Sci Med; 2008; 42(4):411-6. PubMed ID: 19579549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Written pharmaceutical advertising--still unreliable?].
    Gladsø KH; Garberg HR; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2014 Sep; 134(16):1563-8. PubMed ID: 25178232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry--self-regulation in the shadow of federal prosecution.
    Studdert DM; Mello MM; Brennan TA
    N Engl J Med; 2004 Oct; 351(18):1891-900. PubMed ID: 15509824
    [No Abstract]   [Full Text] [Related]  

  • 36. Is banning direct-to-consumer advertising consistent with bioethical principles?
    O'Hara KM
    JAAPA; 2010 Aug; 23(8):54, 56-7. PubMed ID: 20821915
    [No Abstract]   [Full Text] [Related]  

  • 37. From Lydia Pinkham to Bob Dole: what the changing face of direct-to-consumer drug advertising reveals about the professionalism of medicine.
    Pinkus RL
    Kennedy Inst Ethics J; 2002 Jun; 12(2):141-58. PubMed ID: 12476915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development of direct-to-consumer prescription drug advertising regulation.
    Palumbo FB; Mullins CD
    Food Drug Law J; 2002; 57(3):423-43. PubMed ID: 12703509
    [No Abstract]   [Full Text] [Related]  

  • 39. Prescribing controlled substances in Tennessee: progress, not perfection.
    Spickard A; Dodd D; Dixon GL; Pichert JW; Swiggart W
    South Med J; 1999 Jan; 92(1):51-4. PubMed ID: 9932827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physician Exposure to Direct-to-Consumer Pharmaceutical Marketing: Potential for Creating Prescribing Bias.
    Brown JL
    Am J Med; 2017 Jun; 130(6):e247-e248. PubMed ID: 28089801
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.